Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/12/2025 | $8.00 | Overweight | KeyBanc Capital Markets |
| 8/16/2022 | Overweight → Neutral | JP Morgan | |
| 3/7/2022 | $11.00 → $10.00 | Equal-Weight | Morgan Stanley |
| 2/15/2022 | $24.00 → $11.00 | Equal-Weight | Morgan Stanley |
| 11/15/2021 | $26.00 → $24.00 | Equal-Weight | Morgan Stanley |
| 8/9/2021 | Outperform | Cowen | |
| 8/9/2021 | $26.00 | Equal-Weight | Morgan Stanley |
| 8/9/2021 | $28.00 | Buy | Stifel |
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2024 financial results prior to the market open on Friday, February 28, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:00 a.m. ET on Friday, February 28, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and
Fourth quarter 2024 total revenue expected to be a record at approximately $8.2 million, representing growth of approximately 30% compared to the prior-year period. Fourth quarter 2024 recurring revenue expected to be approximately $4.2 million, representing growth of approximately 27% compared to the prior-year period. Full year 2024 total revenue expected to be approximately $28.1 million, representing growth of approximately 25% compared to the prior year. Full year 2024 recurring revenue expected to be approximately $15.5 million, representing growth of approximately 14% compared to the prior year. Announces successful collaboration with Lonza integrating the Growth Direct and Lonza's M
LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference. The Company is scheduled to present on Thursday, January 16, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time). A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. T
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
KeyBanc Capital Markets initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $8.00
JP Morgan downgraded Rapid Micro Biosystems from Overweight to Neutral
Morgan Stanley reiterated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $10.00 from $11.00 previously
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar
LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S
MALVERN, Pa., April 4, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry-leading provider of drug discovery services, today announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Chief Business Officer (CBO) and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company's next stage of growth. "We are thrilled to welcome Rich, a seasoned healthcare finance and operations executive, to the Executive Committee of Reaction Biology," said John H. Johnson, Chief Executive Officer and Director of Reaction Biology. "Having managed large, global biopharmaceut
LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2024 financial results prior to the market open on Friday, February 28, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:00 a.m. ET on Friday, February 28, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and
Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021 Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout Achieved inflection in gross margins to positive 8%, representing a significant company milestone and a 35 percentage point improvement compared to the third quarter of 2023Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 2
LEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2024 financial results prior to the market open on Friday, November 1, 2024. In conjunction with the release, the Company's management team will host a webcast conference call beginning at 9:00 a.m. ET on Friday, November 1, 2024. The live audio webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. A